コンテンツにジャンプ

トップページ > 診療科・共通部門 > 内科系 > 病理・臨床検査科 > 研究について

研究について

病理・臨床検査科の医師は先端医療開発センター臨床腫瘍病理部分野バイオマーカー探索TR分野病理・臨床検査TR分野)と併任になっており、がんの生物学的特性の理解や新規治療法開発を目指した研究に従事しています。また、新規抗がん剤開発にかかわるバイオマーカー検索やコンパニオン診断法の開発にも積極的に取り組んでおり、国際共同治験や東病院で実施される世界に先駆けたFIH (first in human) 試験における病理中央診断を担うなど、さまざまな臨床研究の推進に貢献しています。このほか、2017年に国立がん研究センター東病院が「がんゲノム医療中核拠点病院」に指定されたことに合わせて、病理組織標本を用いた次世代型シークエンサーによる遺伝子変異解析も運用が開始され、国立がん研究センター内外の部門・研究室との共同研究を推進してゆく予定です。
教育、研修に関しては、外科や内科からのローテーションや他大学からの研究生を積極的に受け入れており、検鏡の指導、カンファレンス、学会発表や論文作成など研究指導も行っています。

当センターの病理(病理臨床検査科・臨床腫瘍病理分野)はCOVID-19をきっかけとして、Webを通じた合同研究会を他拠点と定期的に開催し、交流を行っています。

研究の詳細については下記、業績をご参照ください。

合同研究発表会

  • NEW 第5回 がん研究センター中央病院病理診断科との合同研究発表会
    日時:2024年1月16日(火曜日) 9:00~
    特別講演会
    臨床腫瘍病理分野 石川 俊平先生
    「空間ゲノミクスを用いた胃粘膜の生理・病態解析」
  • NEW 第4回 名古屋大学腫瘍病理学教室との合同研究発表会
    日時:2023年12月27日(水曜日) 17:00~19:00
    場所:Teams
    がん研究センター発表者:
    坂下 信悟 「早期食道癌における代謝微小環境の探索」
    滝 哲郎 「肺癌における組織学的な腫瘍内不均一性の定量化とその臨床病理学的意義」
  • 第3回 東京大学・国立がん研究センター(柏)、合同研究発表会
    日時:2023年7月11日(火曜日)18:00~
    がんセンター発表者:
    香川 洋輔(国立がん研究センター東病院 呼吸器内科)
    「Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma」
    小嶋 基寛(国立がん研究センター先端医療開発センター臨床腫瘍病理分野ユニット長)
    「漿膜弾性板浸潤の病理診断における有用性」
  • 第3回 東京医科歯科大学包括病理学教室・人体病理学教室との合同研究発表会
    日時:2023年6月6日(火曜日)17:30~
    がん研究センター発表者:
    足立 将大「病理形態像をもとにしたAIに対する解釈性向上の試み」
  • 第4回 がん研究センター中央病院病理診断科との合同研究発表会
    日時:2023年11月8日(火曜日)9:00~
    がん研究センター(柏)発表者:
    足立 将大「人工知能を用いたヒトパピローマウイルス関連中咽頭癌における病理組織学的特徴の抽出」
    坂本 直也「胃がんオルガノイドを用いた薬剤耐性関連分子の研究」
  • 第3回 名古屋大学腫瘍病理学教室との合同研究発表会
    日時:2022年12月08日(水曜日) 17:00~
    がん研究センター発表者:
    北岡 匠「Quantification of GREM1 throughout the tumor stroma using whole slide imaging and its clinicopathological significance in gastric cancer」
    坂下 信悟「弱教師あり学習を用いた、HPV関連中咽頭癌の特徴量解釈の試み」
  • 第2回 東京大学 人体病理学・病理診断学分野との合同研究発表会
    日時:2022年7月21日(木曜日) 17:00~
    がん研究センター発表者:
    坂下 信悟「異常検知型AIを用いた、細胞診スクリーニングシステム開発の試み」
    村田 翔平「肺腺癌において予後不良と関連する特徴的な血管浸潤像の同定およびその免疫微小環境」
  • 第3回 がん研究センター中央病院病理診断科との合同研究発表会
    日時:2022年06月14日(火曜日)  9:00~
    特別講演会
    日本赤十字社愛知医療センター名古屋第一病院 
    伊藤 雅文先生「造血幹細胞移植の病理」
  • 第2回 東京医科歯科大学包括病理学教室・人体病理学教室との合同研究発表会
    日時:2022年5月25日(水曜日) 17:00~
    がん研究センター発表者:
    坂本 直也「Transcriptome 解析による胃がんオルガノイドを用いた薬剤耐性関連分子の研究」
  • 第2回 名古屋大学腫瘍病理学教室との合同研究発表会
    日時:2021年12月15日(水曜日) 17:00~
    がん研究センター発表者:
    野村 幸太郎「肺腺癌のリンパ節転移巣における腫瘍微小環境に関する研究」
    原田 健司 「抗癌剤耐性オルガノイドの樹立とその解析」
  • 第2回 がん研究センター中央病院病理診断科との合同研究発表会
    日時:2021年10月19日(火曜日) 9:00~
    がん研究センター(柏)発表者:
    黒江 崇史 (柏) 「腎細胞癌における dirty necrosis の臨床病理学的特徴」
  • 第1回 東京大学 人体病理学・病理診断学分野との合同研究発表会
    日時:2021年07月01日(木曜日) 17:00~
    がん研究センター発表者:
    黒江 崇史「腎細胞癌における dirty necrosis (DN) の臨床病理学的検討」
    森末 遼 「肉腫様ないし未分化像を有する肝細胞癌の臨床病理学的検討」
  • 第1回 がん研究センター中央病院病理診断科との合同研究発表会
    日時:2020年12月22日(火曜日) 9:00~
    がん研究センター(柏)発表者:
    鈴木 敏之「肝胆膵腫瘍における物性と臨床病理学的因子との関連について」
  • 第1回 名古屋大学腫瘍病理学教室との合同研究発表会
    日時:2020年11月25日(水曜日) 17:00~
    がん研究センター発表者:
    森末 遼「肉腫様ないし未分化像を有する肝細胞癌における腫瘍免疫微小環境の特徴」
    坂本 直也「消化管がんオルガノイドを用いた抗がん剤耐性に関する検討」
  • 第1回 東京医科歯科大学包括病理学教室・人体病理学教室との合同研究発表会
    日時:2020年1月20日(水曜日) 17:00~
    がん研究センター発表者:
    小嶋 基寛「腫瘍の物性と臨床病理組織学的因子の関連」

業績

2025年

  1. NEW Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Miyaaki H, Nakao K, Shitara K. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. Gastric Cancer. 28(1):63-73, 2025
  2. NEW Sugawara K, Sakashita S, Fukuda T, Murakami C, Oka D, Amori G, Ishibashi K, Kobayashi Y, Kanda H, Motoi N. Survival Impacts of Mitochondrial Status in Esophageal Squamous Cell Carcinoma Patients. Ann Surg Oncol. 32(3):1963-1972, 2025
  3. NEW Kajiyama D, Fujiwara N, Shigeno T, Sato K, Yamaguchi M, Sakashita S, Daiko H, Fujita T. Impact of Lymphatic and Venous Invasion Patterns on Postoperative Prognosis and Distant Metastasis in Esophageal Squamous Cell Carcinoma After Preoperative Chemotherapy. Ann Surg Oncol. 32(2):860-871, 2025
  4. NEW Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. NETosis in pulmonary pleomorphic carcinoma. Cancer Sci. 116(2):524-532, 2025
  5. NEW Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib. J Thorac Oncol. 20(2):177-193, 2025
  6. NEW Kojima N, Nishino S, Sasahara Y, Taki T, Imada H, Miyoshi T, Watanabe SI, Ishii G, Yatabe Y, Mori T, Yoshida A. Inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion: a report of two cases and a potential relationship with clear cell stromal tumour. Histopathology. 86(3):365-372, 2025
  7. NEW Nagata H, Kinoshita T, Sakashita S, Kojima M, Taki T, Kuwata T, Yura M, Shitara K, Ishii G, Sakamoto N. Area of Residual Tumor Measurement After Preoperative Chemotherapy as an Objective and Quantitative Method for Predicting the Prognosis of Gastric Cancer: A Single-Center Retrospective Study. World J Surg. 2025 Online ahead of print.

2024年

  1. NEW Yoshimoto M, Washiyama K, Ohnuki K, Doi A, Inokuchi M, Kojima M, Miller BW, Yoshii Y, Inaki A, Fujii H. Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma. Pharmaceutics. 17(1):9, 2024
  2. NEW Sakai SA, Saeki K, Chi S, Hamaya Y, Du J, Nakamura M, Hojo H, Kojima T, Nakamura Y, Bando H, Kojima M, Suzuki A, Suzuki Y, Akimoto T, Tsuchihara K, Haeno H, Yamashita R, Kageyama SI. Mathematical modeling predicts optimal immune checkpoint inhibitor and radiotherapy combinations and timing of administration. Cancer Immunol Res. 2024 Online ahead of print.
  3. NEW Igata Y, Kudo M, Kojima M, Kami S, Aoki K, Satake T, Kobayashi T, Sugimoto M, Kobayashi S, Konishi M, Gotohda N. Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report. World J Clin Cases. 12(34):6721-6727, 2024
  4. NEW Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol. 2024 Online ahead of print.
  5. NEW Tomi Y, Kinoshita T, Yura M, Sakamoto N, Fujita T, Tokunaga M, Kinugasa Y. Accuracy of the preoperative estimation of esophageal invasion length of adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement. Surg Today. 2024 Online ahead of print.
  6. NEW Inaba A, Ikematsu H, Kojima M, Sakamoto N, Wakabayashi M, Sunakawa H, Nakajo K, Murano T, Kadota T, Shinmura K, Yano T. Association between pathological T1 colorectal cancer with lymphoid follicular replacement and risk of lymph node metastasis. J Gastroenterol Hepatol. 39(12):2631-2638, 2024
  7. NEW Oda S, Kuno H, Fujita T, Hiyama T, Kotani D, Kadota T, Sakashita S, Kobayashi T. Clinical usefulness of four-dimensional dynamic ventilation CT for borderline resectable locally advanced esophageal cancer. Jpn J Radiol. 2024 Online ahead of print.
  8. NEW Minakata N, Kadota T, Sakashita S, Inaba A, Sunakawa H, Takashima K, Nakajo K, Murano T, Shinmura K, Yoda Y, Ikematsu H, Fujita T, Kinoshita T, Yano T. Tumor thickness is associated with metastasis in patients with submucosal invasive adenocarcinoma of the esophagogastric junction. Dis Esophagus. 37(12):doae083, 2024
  9. NEW Tanaka H, Koga Y, Sugahara M, Fuchigami H, Ishikawa A, Yamaguchi T, Banba A, Shinozaki T, Matsuura K, Hayashi R, Sakashita S, Yasunaga M, Yano T. Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy. Pharmaceuticals (Basel). 17(9):1246, 2024
  10. NEW Iida N, Qin M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y. Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clin Cancer Res. 30(18):4167-4178, 2024
  11. NEW Fujii S, Katada C, Watanabe H, Shimoda T, Ochiai A, Yokoyama T, Sakamoto Y, Kano K, Ichinoe M, Nemoto T, Fujita M, Tateishi Y, Sugiura H, Mikami T, Yano T, Kato T, Muto M, Hayashi R. Tumor thickness as a novel risk factor for lymph node metastasis by superficial squamous cell carcinoma of head and neck. Cancer Sci. 115(9):3169-3179, 2024
  12. NEW Odate T, Satomi K, Kubo T, Matsushita Y, Ueno T, Kurose A, Shomori K, Nakai T, Watanabe R, Segawa K, Ohshika S, Miyake N, Kudo S, Shimoi T, Kobayashi E, Komiyama M, Yoshimoto S, Nakatani F, Kawai A, Yatabe Y, Kohsaka S, Ichimura K, Ichikawa H, Yoshida A. Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases. Mod Pathol. 37(1):100359, 2024
  13. NEW Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer Discov. 14(11):2243-2261, 2024
  14. NEW Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, Tane K, Samejima J, Taki T, Hayashi T, Matsubayashi J, Ishii G, Nishikawa H, Ikeda N, Tsuboi M. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clin Cancer Res. 30(24):5584-5592, 2024
  15. NEW Ishii G. New insights into cancer pathology learned from the dynamics of cancer-associated fibroblasts. Pathol Int. 74(9):493-507, 2024
  16. NEW Kubota S, Taki T, Miyoshi T, Tane K, Samejima J, Aokage K, Wakabayashi M, Nomura K, Nagamine M, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Ishii G. Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma. Eur J Cancer. 207:114184, 2024
  17. NEW Takano Y, Suzuki J, Nomura K, Fujii G, Zenkoh J, Kawai H, Kuze Y, Kashima Y, Nagasawa S, Nakamura Y, Kojima M, Tsuchihara K, Seki M, Kanai A, Matsubara D, Kohno T, Noguchi M, Nakaya A, Tsuboi M, Ishii G, Suzuki Y, Suzuki A. Spatially resolved gene expression profiling of tumor microenvironment reveals key steps of lung adenocarcinoma development. Nat Commun. 15(1):10637, 2024
  18. NEW Taki T, Koike Y, Adachi M, Sakashita S, Sakamoto N, Kojima M, Aokage K, Ishikawa S, Tsuboi M, Ishii G. A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis. Cancer Sci. Nov;115(11):3804-3816, 2024
  19. NEW Adachi M, Taki T, Kojima M, Sakamoto N, Matsuura K, Hayashi R, Tabuchi K, Ishikawa S, Ishii G, Sakashita S. Predicting lymph node recurrence in cT1-2N0 tongue squamous cell carcinoma: collaboration between artificial intelligence and pathologists. J Pathol Clin Res. 10(5):e12392, 2024
  20. NEW Kitaoka T, Harada K, Sakashita S, Kojima M, Taki T, Kuwata T, Kinoshita T, Futakuchi M, Ishii G, Sakamoto N. Quantification of Gremlin 1 throughout the tumor stroma using whole slide imaging and its clinicopathological significance in gastric cancer. Virchows Arch. 485(6):1107-1116, 2024
  21. NEW Kaminuma Y, Nakai T, Aokage K, Taki T, Miyoshi T, Tane K, Samejima J, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanabe R, Tsuboi M, Ishii G. Prognostic significance of micronest in cancer stroma in resected lung squamous cell carcinoma. Hum Pathol. 150:20-28, 2024
  22. NEW Urabe A, Adachi M, Sakamoto N, Kojima M, Ishikawa S, Ishii G, Yano T, Sakashita S. Deep learning detected histological differences between invasive and non-invasive areas of early esophageal cancer. Cancer Sci. 2024 Online ahead of print.
  23. NEW Niimi T, Samejima J, Koike Y, Miyoshi T, Tane K, Aokage K, Taki T, Ishii G, Tsuboi M. A case of lung metastasis from gastric cancer presenting as ground-glass opacity dominant nodules. J Cardiothorac Surg. 19(1):365, 2024
  24. NEW Sasaki T, Oda S, Kuno H, Hiyama T, Taki T, Takahashi S, Ishii G, Tsuboi M, Kobayashi T. Potential of spectral imaging generated by contrast-enhanced dual-energy CT for lung cancer histopathological classification - A preliminary study. Eur J Radiol Open. 14:100628, 2024
  25. Kuwata T. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma. Pathol Int. 74(6):301-316, 2024
  26. Shirane Y, Fujii Y, Ono A, Nakahara H, Hayes CN, Miura R, Murakami S, Sakamoto N, Uchikawa S, Fujino H, Nakahara T, Murakami E, Yamauchi M, Miki D, Kawaoka T, Arihiro K, Tsuge M, Oka S. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers (Basel). 16(7):1328, 2024
  27. Hoshi Y, Enokida T, Tamura S, Nakashima T, Okano S, Fujisawa T, Sato M, Wada A, Tanaka H, Takeshita N, Tanaka N, Onaga R, Kishida T, Uryu H, Sakashita S, Asakage T, Tahara M. Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma. Front Oncol. 14:1379013, 2024
  28. Habu T, Kumagai S, Bando H, Fujisawa T, Mishima S, Kotani D, Nakamura M, Hojo H, Sakashita S, Kinoshita T, Yano T, Mitsunaga S, Nishikawa H, Koyama S, Kojima T. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma. J Gastroenterol. 59(9):798-811, 2024.
  29. Miyasaka Y, Hiyama T, Kuno H, Shinozaki T, Tomioka T, Sakashita S, Kobayashi T. Imaging of salivary gland cancers derived from a sublingual gland herniated into the submandibular space: a report of three cases. Neuroradiology. 66(6):931-935, 2024
  30. Sakashita M, Motoi N, Yamamoto G, Gambe E, Suzuki M, Yoshida Y, Watanabe SI, Takazawa Y, Aoki K, Ochiai A, Sakashita S. An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections. J Cancer Res Clin Oncol. 150(4):172, 2024
  31. Okunaka M, Kotani D, Fujiwara H, Sato K, Fujiwara N, Mishima S, Sakashita S, Yoshino T, Fujita T, Kojima T. Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. Ther Adv Med Oncol. 16:17588359241229432, 2024
  32. Cai L, Gao Y, DeBerardinis RJ, Acquaah-Mensah G, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Grüner BM, Jia D, Jones R, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz Lopez MC, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll H, Moorehead R, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos Lafuente M, Snyder E, Sotillo R, Su KY, Taki T, Taparra K, Xia Y, van Veen E, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna JD. A Lung Cancer Mouse Model Database. bioRxiv [Preprint]. 2024
  33. Hashimoto T, Nakamura Y, Mishima S, Nakayama I, Kotani D, Kawazoe A, Kuboki Y, Bando H, Kojima T, Iida N, Shibuki T, Imai M, Fujisawa T, Nagamine M, Sakamoto N, Kuwata T, Yoshino T, Shitara K. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer Sci. 115(5):1622-1633, 2024
  34. Tamaru Y, Kuwai T, Kajiwara Y, Oka S, Saito S, Fukunaga Y, Kawachi H, Takamatsu M, Hotta K, Ikematsu H, Kojima M, Saito Y, Kanemitsu Y, Yamada M, Sekine S, Tanaka S, Nagata S, Nakamura T, Yamada K, Konno M, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Nakai K, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H. Long-term outcomes of additional surgery after endoscopic resection versus primary surgery for T1 colorectal cancer. Am J Gastroenterol. 119(12):2418-2425, 2024
  35. Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, Kotani D, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Sato A, Nishikawa H, Ito M, Yoshino T. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Br J Cancer. 131(2):283-289, 2024
  36. Suzuki Y, Hasegawa H, Mori T, Teramura K, Tsukada Y, Sasaki T, Kojima M, Ito M. Cytological Analysis of the Surgical Field During Transanal Total Mesorectal Excision for Rectal Cancer: A Prospective Study. Dis Colon Rectum. 67(8):1009-1017, 2024
  37. Minamide T, Ikematsu H, Kajiwara Y, Oka S, Ajioka Y, Ueno H; Japanese Society for Cancer of the Colon and Rectum. Impact of Lesion Location on Recurrence After Resection of T1 Colorectal Cancer: Post Hoc Analysis of a Nationwide Multicenter Cohort Study. Gastroenterology. 166(1):198-201.e3, 2024
  38. Tsushima T, Sato N, Guo YM, Nakamura H, Kunisada K, Chi SG, Akie K, Takahashi Y, Nakamura S, Shimada K, Ishii G, Minami Y, Yuda J. Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment. EJHaem. 5(3):642-645, 2024
  39. Goto E, Taki T, Nomura K, Miyakami Y, Miyoshi T, Tane K, Samejima J, Aokage K, Nagamine M, Sakashita S, Sakamoto N, Kojima M, Suzuki K, Tsuboi M, Ishii G. Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern. Lung Cancer. 192:107830, 2024
  40. Nagasaki Y, Taki T, Nomura K, Tane K, Miyoshi T, Samejima J, Aokage K, Ohtani-Kim SJ, Kojima M, Sakashita S, Sakamoto N, Ishikawa S, Suzuki K, Tsuboi M, Ishii G. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer. J Natl Cancer Inst. 116(7):1158-1168, 2024
  41. Adachi M, Taki T, Sakamoto N, Kojima M, Hirao A, Matsuura K, Hayashi R, Tabuchi K, Ishikawa S, Ishii G, Sakashita S. Extracting interpretable features for pathologists using weakly supervised learning to predict p16 expression in oropharyngeal cancer. Sci Rep. 14(1):4506, 2024
  42. Tabata S, Umemura S, Narita M, Udagawa H, Ishikawa T, Tsuboi M, Goto K, Ishii G, Tsuchihara K, Ochiai A, Kobayashi SS, Soga T, Makinoshima H. Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma. Mol Cancer Res. 22(1):82-93, 2024
  43. Oka S, Tanaka S, Kajiwara Y, Saito S, Fukunaga Y, Takamatsu M, Kawachi H, Hotta K, Ikematsu H, Kojima M, Saito Y, Yamada M, Kanemitsu Y, Sekine S, Nagata S, Yamada K, Kobayashi N, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Eda H, Uraoka T, Akimoto N, Kobayashi H, Sugihara K, Ueno H. Treatment Decision for Locally Resected T1 Colorectal Carcinoma-Verification of the Japanese Guideline Criteria for Additional Surgery Based on Long-Term Clinical Outcomes. Am J Gastroenterol. 119(10):2019-2027, 2024
  44. Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M, Sakamoto N, Kojima M, Kuwata T, Yoshino T, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer. J Immunother Cancer. 12(2):e008210, 2024
  45. Kagoura M, Kobayashi S, Kojima M, Kudo M, Sugimoto M, Konishi M, Gotohda N. Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone. Eur J Surg Oncol. 50(3):107980, 2024
  46. Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. J Exp Med. 221(3):e20232028, 2024
  47. Sasaki T, Kuno H, Hiyama T, Oda S, Masuoka S, Miyasaka Y, Taki T, Nagasaki Y, Ohtani-Kim SJ, Ishii G, Kaku S, Shroff GS, Kobayashi T. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation. Radiographics. 44(3):e230136, 2024
  48. Nomura K, Aokage K, Kaminuma Y, Nakai T, Wakabayashi M, Ikeno T, Koike Y, Taki T, Miyoshi T, Tane K, Samejima J, Ishii G, Tsuboi M. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system. Int J Clin Oncol. 29(3):248-257, 2024
  49. Niimi T, Samejima J, Wakabayashi M, Miyoshi T, Tane K, Aokage K, Taki T, Nakai T, Ishii G, Kikuchi A, Yoshioka E, Yokose T, Ito H, Tsuboi M. Ten-year follow-up outcomes of limited resection trial for radiologically less-invasive lung cancer. Jpn J Clin Oncol. 54(4):479-488, 2024
  50. Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation. Lung Cancer. 188:107453, 2024

2023年

  1. Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Suzuki Y, Akagi K, Nomura S, Fujii S, Sugiyama M, Nishida N, Mizokami M, Koh Y, Koshizaka T, Okada H, Abe Y, Ohtsu A, Yoshino T, Tsuchihara K. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. Int J Clin Oncol. 28(5):654-663, 2023
  2. Arai N, Hattori N, Yamashita S, Liu YY, Ebata T, Takeuchi C, Takeshima H, Fujii S, Kondo H, Mukai H, Ushijima T.  HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity. Breast Cancer Res Treat. 201(2):317-328, 2023
  3. Oda S, Kuno H, Hiyama T, Sakashita S, Sasaki T, Kobayashi T. Reply to letter to the editor: Computed tomography-based radiomic analysis for predicting pathological response and prognosis after neoadjuvant chemotherapy in patients with locally advanced esophageal cancer. Abdom Radiol (NY). 48(9):3035-3037, 2023
  4. Mitsui T, Mori A, Takamatsu T, Kadota T, Sato K, Fukushima R, Okubo K, Umezawa M, Takemura H, Yokota H, Kuwata T, Kinoshita T, Ikematsu H, Yano T, Maeda S, Soga K. Evaluating the identification of the extent of gastric cancer by over-1000 nm near-infrared hyperspectral imaging using surgical specimens. J Biomed Opt. 28(8):086001, 2023
  5. Konishi Y, Taki T, Nakai T, Kuroe T, Morisue R, Miyoshi T, Tane K, Samejima J, Aokage K, Miyazaki S, Sakamoto N, Sakashita S, Watanabe R, Kojima M, Suzuki K, Tsuboi M, Ishii G. Clinicopathological features and prognostic impact of dirty necrosis in metastatic lung cancers from the colon and rectum. Cancer Sci. 114(5):2169-2177, 2023
  6. Adachi M, Aoyama N, Kojima M, Sakamoto N, Miyazaki S, Taki T, Watanabe R, Matsuura K, Kotani D, Kojima T, Fujita T, Tabuchi K, Ishii G, Sakashita S. The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 149(8):4663-4673, 2023
  7. Oyoshi H, Du J, Sakai SA, Yamashita R, Okumura M, Motegi A, Hojo H, Nakamura M, Hirata H, Sunakawa H, Kotani D, Yano T, Kojima T, Nakamura Y, Kojima M, Suzuki A, Zenkoh J, Tsuchihara K, Akimoto T, Shibata A, Suzuki Y, Kageyama SI. Comprehensive single-cell analysis demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumor in esophageal squamous cell carcinoma. Sci Adv. 9(50):eadh9069, 2023
  8. Minamide T, Ikematsu H, Kajiwara Y, Oka S, Ajioka Y, Ueno H; Japanese Society for Cancer of the Colon and Rectum. Impact of Lesion Location on Recurrence After Resection of T1 Colorectal Cancer: Post Hoc Analysis of a Nationwide Multicenter Cohort Study. Gastroenterology. 2023 Online ahead of print.
  9. Satake T, Shibuki T, Watanabe K, Sasaki M, Imaoka H, Mitsunaga S, Kojima M, Ikeda M. Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Front Oncol. 13:1234113, 2023 eCollection
  10. Du J, Kageyama SI, Yamashita R, Tanaka K, Okumura M, Motegi A, Hojo H, Nakamura M, Hirata H, Sunakawa H, Kotani D, Yano T, Kojima T, Hamaya Y, Kojima M, Nakamura Y, Suzuki A, Suzuki Y, Tsuchihara K, Akimoto T. Transposable elements potentiate radiotherapy-induced cellular immune reactions via RIG-I-mediated virus-sensing pathways. Commun Biol. 6(1):818, 2023
  11. Kondo R, Sakamoto N, Harada K, Hashimoto H, Morisue R, Yanagihara K, Kinoshita T, Kojima M, Ishii G. Cancer-associated fibroblast-dependent and -independent invasion of gastric cancer cells. J Cancer Res Clin Oncol. 149(8):5309-5319, 2023
  12. Takeshita N, Enokida T, Okano S, Fujisawa T, Wada A, Sato M, Tanaka H, Tanaka N, Onaga R, Hoshi Y, Sakashita S, Ishii G, Tahara M. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Oral Oncol. 147:106615, 2023
  13. Tanabe K, Nakanishi Y, Okubo N, Matsumoto S, Umino Y, Kataoka M, Yajima S, Yoshida T, Miyazaki S, Kuwata T, Ishii G, Watanabe R, Masuda H. Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II. BMC Cancer. 5;23(1):940, 2023
  14. Tanaka T, Umemura S, Miyoshi T, Nakai T, Noritake O, Suzuki J, Tane K, Samejima J, Aokage K, Mimaki S, Tsuchihara K, Taki T, Miyazaki S, Watanabe R, Sakashita S, Sakamoto N, Kojima M, Goto K, Ikeda N, Tsuboi M, Ishii G. The prognostic impact of a high number of peritumoral alveolar macrophages in neuroendocrine carcinoma in the lung. Pathol Int. 73(10):497-508, 2023
  15. Morisue R, Kojima M, Suzuki T, Watanabe R, Sakamoto N, Sakashita S, Harada K, Nakai T, Ishii G, Nakatsura T, Gotohda N, Ishikawa S. Common clinicopathological and immunological features of sarcomatoid carcinoma across organs: A histomorphology-based cross-organ study. Int J Cancer. 153(12):1997-2010, 2023
  16. Furue Y, Hori K, Tomioka T, Fujii S, Okano W, Shinozaki T, Kadota T, Yoda Y, Hayashi R, Yano T. Clinical outcome of endoscopic-assisted transoral surgery for superficial cancer of pharyngo-esophageal junction. Head Neck. 45(8):2098-2107, 2023
  17. Miyasaka Y, Hiyama T, Kuno H, Shinozaki T, Sakashita S, Kobayashi T. Characteristic imaging findings in a patient with chronic expanding hematoma on the floor of the mouth. Int Cancer Conf J. 12(3):185-189, 2023
  18. Kojima M, Yokota M, Yanagisawa N, Kitamura S, Amemiya K, Kawano S, Tsukada Y, Sakuyama N, Nagayasu K, Hashimoto T, Nakashima K, Jiang K, Kanemitsu Y, Fujita F, Akiba J, Notohara K, Itakura J, Sekine S, Sakashita S, Sakamoto N, Ishikawa S, Nakanishi Y, Yao T, Liang WY, Lauwers GY, Ito M, Sakamoto K, Ishii G, Ochiai A. Assessment of Elastic Laminal Invasion Contributes to an Objective pT3 Subclassification in Colon Cancer. Am J Surg Pathol. 47(10):1122-1133, 2023
  19. Igata Y, Kojima M, Suzuki T, Ishii G, Morisue R, Suzuki T, Kudo M, Sugimoto M, Kobayashi S, Martin JD, Stylianopoulos T, Cabral H, Kano MR, Konishi M, Gotohda N. Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma. Cancer Sci. 114(9):3783-3792, 2023
  20. Minakata N, Sakashita S, Wakabayashi M, Nakamura Y, Sunakawa H, Yoda Y, Ishii G, Yano T. Immunohistochemistry and oxygen saturation endoscopic imaging reveal hypoxia in submucosal invasive esophageal squamous cell carcinoma. Cancer Med. 12(15):15809-15819, 2023
  21. Kagawa Y, Nakai T, Taki T, Hashimoto H, Tanaka Y, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Watanabe R, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Goto K, Ishii G. Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma. Cancer Sci. 2114(8):3423-3432, 023
  22. Feng W, Inoue R, Kuwata T, Niikura N, Fujii S, Kumaki N, Honda K, Xu LA, Goetz A, Gaule P, Cogswell J, Rimm DL, McGee R. Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens. Appl Immunohistochem Mol Morphol. 31(5):339-345, 2023
  23. Oda S, Kuno H, Hiyama T, Sakashita S, Sasaki T, Kobayashi T. Computed tomography-based radiomic analysis for predicting pathological response and prognosis after neoadjuvant chemotherapy in patients with locally advanced esophageal cancer. Abdom Radiol (NY). 48(8):2503-2513, 2023
  24. Ohtani-Kim SJ, Taki T, Tane K, Miyoshi T, Samejima J, Aokage K, Nagasaki Y, Kojima M, Sakashita S, Watanabe R, Sakamoto N, Goto K, Tsuboi M, Ishii G. Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma. Mod Pathol. 36(9):100209, 2023
  25. Yoshida T, Yatabe Y, Kato K, Ishii G, Hamada A, Mano H, Sunami K, Yamamoto N, Kohno T. The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan. Cancer Biol Med. 2023 Online ahead of print.
  26. Akimoto E, Kuwata T, Shitara K, Kawazoe A, Sakamoto N, Ishii G, Ochiai A, Kinoshita T. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery. Ann Surg Oncol. 30(8):5227-5236, 2023
  27. Morishita Y, Sakashita S, Tomioka T, Okano W, Shinozaki T, Higashino T, Matsuura K, Hayashi R. Human papillomavirus-related multiphenotypic sinonasal carcinoma. Auris Nasus Larynx. 50(1):151-155, 2023
  28. Masuoka S, Hiyama T, Kuno H, Sekiya K, Sakashita S, Kobayashi T. Imaging Approach for Cervical Lymph Node Metastases from Unknown Primary Tumor. Radiographics. 43(3):e220071, 2023
  29. Kajiwara Y, Oka S, Tanaka S, Nakamura T, Saito S, Fukunaga Y, Takamatsu M, Kawachi H, Hotta K, Ikematsu H, Kojima M, Saito Y, Yamada M, Kanemitsu Y, Sekine S, Nagata S, Yamada K, Kobayashi N, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Eda H, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H. Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: A nationwide, multicenter study. Gastrointest Endosc. S0016-5107(23)00026-3, 2023
  30. Matsuda Y, Ye J, Yamakawa K, Mukai Y, Azuma K, Wu L, Masutomi K, Yamashita T, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Kojima M, Kaneko S, Haba R, Kontani K, Kanaji N, Okano K, Muto-Ishizuka M, Yokohira M, Saoo K, Imaida K, Suizu F. Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worse prognosis. J Natl Cancer Inst. 115(2):208-218, 2023
  31. Morii E, Hatanaka Y, Motoi N, Kawahara A, Hamakawa S, Kuwata T, Nagatomo T, Oda Y, Okamoto A, Tanaka R, Iyoda A, Ichiro M, Matsuo Y, Nakamura N, Nakai T, Fukuhara M, Tokita K, Yamaguchi T, Takenaka M, Kawabata A, Hatanaka KC, Tsubame K, Satoh Y; Working Group on Cytology in the Era of Genomic Medicine. Guidelines for Handling of Cytological Specimens in Cancer Genomic Medicine. Pathobiology. 8:1-23, 2023
  32. Tanaka Y, Nakai T, Suzuki A, Kagawa Y, Noritake O, Taki T, Hashimoto H, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanbe R, Tsuboi M, Goto K, Ishii G. Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma. Cancer Immunol Immunother. 72(7):2205-2215, 2023.
  33. Sakashita S, Sakamoto N, Kojima M, Taki T, Miyazaki S, Minakata N, Sasabe M, Kinoshita T, Ishii G, Ochiai A. Requirement of image standardization for AI-based macroscopic diagnosis for surgical specimens of gastric cancer. J Cancer Res Clin Oncol. 149(9):6467-6477, 2023
  34. Kuroe T, Watanabe R, Morisue R, Miyazaki S, Kojima M, Murata SC, Nakai T, Taki T, Sakashita S, Sakamoto N, Matsubara N, Masuda H, Ushiku T, Ishii G. Dirty necrosis in renal cell carcinoma is associated with NETosis and systemic inflammation. Cancer Med. 12(4):4557-4567, 2023.
  35. Sakai T, Aokage K, Miyoshi T, Tane K, Ishii G, Goto K, Tsuboi M. Tumor size exceeding 5 cm as a valid prognostic factor in all stages of thymic epithelial tumors. Surg Today. 53(1):42-50, 2023
  36. Murano T, Ikematsu H, Shinmura K, Okumura K, Kuwata T, Ushiama M, Yoshida T, Takashima K, Nakajo K, Kadota T, Yoda Y, Oono Y, Yano T. Endoscopic management of familial adenomatous polyposis targeting colorectal lesions greater than 5 mm in size: a single-center retrospective study. Fam Cancer. 22(1):83-89, 2023
  37. Nakagama Y, Chi SG, Minami Y, Watanabe R, Yamagishi M, Atsuko U, Kido Y. Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination. J Infect Chemother. 29(1):112-114, 2023
  38. Kotani D, Nakamura Y, Fujisawa T, Bando H, Sakamoto N, Johns AL, Park K; ICGC-ARGO, Casolino R, Yoshino T, Biankin AV. ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. Lancet Oncol. 24(1):20-21, 2023

更新日:2025年3月19日